Cambrex Unveils 0 Million Funding to Extend API Production and Enhance U.S. Drug Provide Resilience
Insights and updates

Cambrex Unveils $120 Million Funding to Extend API Production and Enhance U.S. Drug Provide Resilience


EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ — Cambrex, a chief international word building and production group (CDMO), nowadays introduced a $120 million funding to extend its U.S. operations, addressing higher call for for API building and production, and accelerating the corporate’s management position within the fast-growing peptide therapeutics marketplace.

“Our customers, in partnership with federal and state agencies, are reshoring drug manufacturing in the U.S., the world’s largest pharmaceutical market. Local API production is vital for supply chain security and resilience, and Cambrex will play a key role. We are seeing very strong demand from our customers to partner with Cambrex to utilize this expanded capacity,” commented Thomas Loewald, CEO of Cambrex.

The $120 million funding will aid a 40% build up within the Charles Town, Iowa website’s large-scale production capability, achieving just about a million liters. The Charles Town facility, positioned on a 45-acre website, manufactures a vast territory of APIs and pharmaceutical intermediates, together with extremely potent molecules and regulated components.

“With rising demand for U.S.-based supply chains for critical therapies, Cambrex is focused on supporting the long-term stability of pharmaceutical manufacturing in the United States,” Loewald added. “The investment in our Charles City facility, the nation’s largest independent API manufacturing site, reflects our commitment to meeting clients’ evolving needs for small molecule and peptide manufacturing.”

These days’s loyalty builds on Cambrex’s heritage of making an investment in its drug building and production community, and follows earlier expansions over the date 5 years, together with:

  • The addition of extremely potent API and large-scale production capability in Charles Town, Iowa. (2022)
  • Pristine, state of the art laboratories, scientific and small-to-medium quantity business production capability, designed for business remedies concentrated on uncommon sicknesses and orphan designations, in Prime Level, North Carolina. (2023)
  • Expanded functions and pristine GMP production capability for peptide therapeutics in Waltham, Massachusetts. (2025)

Cambrex’s persevered investments underscore its loyalty to including functions and lengthening capability to satisfy the evolving wishes and rising call for of the pharmaceutical business.

About Cambrex
Cambrex is a chief international word building and production group (CDMO) that gives drug substance building and production throughout all the drug lifecycle, in addition to complete analytical and IND enabling services and products.

With over 40 years of enjoy and a crew of two,000 mavens servicing international shoppers from North The united states and Europe, Cambrex do business in a territory of specialised drug substance applied sciences and functions, together with steady current, managed components, peptide synthesis, solid-state science, subject matter characterization, and extremely potent APIs. 

Emblem – https://mma.prnewswire.com/media/2236065/5463220/Cambrex_logo.jpg

SOURCE Cambrex



Source link